Nurix says Sanofi ends STAT6 degrader trial, program
Reuters reported that Nurix Therapeutics said Sanofi is discontinuing an oral STAT6 degrader in Phase 1 and ending that autoimmune collaboration program.
What's new
- New headline Was: “Nurix says Sanofi discontinues autoimmune disease drug program”
- Our desk filed its story
